Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Neurology

• Publication date

  2015-07-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-015-7837-xPMID 26162713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease

  2015cited by this paper
• Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt–Jakob disease

  2015cited by this paper
• Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

  2015cited by this paper
• Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease

  2015cited by this paper
• Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.

  2014cited by this paper
• Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

  2014cited by this paper
• Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation

  2014cited by this paper
• Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

  2014cited by this paper
• Characteristic CSF Prion Seeding Efficiency in Humans with Prion Diseases

  2014cited by this paper
• Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

  2013cited by this paper
• Using Cerebrospinal Fluid Marker Profiles in Clinical Diagnosis of Dementia with Lewy Bodies, Parkinson's Disease, and Alzheimer's Disease

  2013cited by this paper
• Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

  2013cited by this paper
• Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years

  2012cited by this paper
• α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system

  2012cited by this paper
• Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease

  2012cited by this paper
• Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid.

  2012cited by this paper
• Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

  2011influential reference
• Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion

  2011cited by this paper
• Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease

  2011cited by this paper
• Rapidly progressive Alzheimer disease.

  2011cited by this paper
• DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

  2010cited by this paper
• Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease

  2009cited by this paper
• Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease

  2009cited by this paper
• CSF amyloid‐β 1‐38 and 1‐42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

  2008cited by this paper
• Molecular mechanisms of prion pathogenesis.

  2008cited by this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cited by this paper
• Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance.

  2007influential reference
• Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis

  2007cited by this paper
• Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias

  2007cited by this paper
• Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

  2006cited by this paper
• CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease

  2006cited by this paper
• Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease.

  2006cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias

  2003cited by this paper
• Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

  2002cited by this paper
• Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease

  2000cited by this paper
• Decreased Levels of Amyloid-β 1-42 in Cerebrospinal Fluid of Creutzfeldt–Jakob Disease Patients

  1999cited by this paper
• Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study

  1998cited by this paper
• Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease

  1998cited by this paper

• Uncoupling of CSF biomarkers and clinical status in patients with a novel mutation of ATP13a2

  2025cites this paper
• Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease

  2022cites this paper
• Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline

  2022cites this paper
• Role of Biomarkers for the Diagnosis of Prion Diseases: A Narrative Review

  2022cites this paper
• Machine Learning-Assisted Pattern Recognition of Amyloid Beta Aggregates with Fluorescent Conjugated Polymers and Graphite Oxide Electrostatic Complexes.

  2022cites this paper
• Development of biofluid biomarkers for Huntington’s disease

  2020cites this paper
• Biomarker in der Diagnostik und Differentialdiagnostik der vaskulären Demenz bei zerebraler Mikroangiopathie

  2019influential citation
• Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients

  2019cites this paper
• Seeding and structural varibility in α-synucleinopathies

  2019cites this paper
• Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease

  2018cites this paper
• Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy

  2018cites this paper
• Evaluation of α‐synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases

  2017cites this paper
• Cerebrospinal fluid in Creutzfeldt-Jakob disease.

  2017cites this paper
• Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation.

  2017cites this paper
• Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

  2017cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia

  2017cites this paper
• Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease

  2017cites this paper
• Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies*

  2016influential citation
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016influential citation
• The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases

  2016cites this paper
• Antemortem Diagnostics in Prion Disease

  2016cites this paper
• Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies

  2016influential citation